Lirilumab: Phase II started

Bristol-Myers Squibb began an open-label, U.S. Phase II trial to evaluate 3 mg/kg IV lirilumab on day 1 of each 28-day cycle for up to 24 cycles plus IV Rituxan rituximab for 12 cycles in about 48 pa...